ATIM-33. NOA-16: A FIRST-IN-MAN MULTICENTER PHASE I CLINICAL TRIAL OF THE GERMAN NEUROONCOLOGY WORKING GROUP EVALUATING A MUTATION-SPECIFIC PEPTIDE VACCINE TARGETING IDH1R132H IN PATIENTS WITH NEWLY DIAGNOSED MALIGNANT ASTROCYTOMASMichael Platten, Wolfgang Wick, Lukas Bunse et al.|Neuro-Oncology|2018Cited by 26
Establishment of a 3D Model to Characterize the Radioresponse of Patient-Derived Glioblastoma CellsZoe Strand, Daniela Schilling|Cancers|2023Cited by 3